Prime Therapeutics discusses the challenges health plans face in expanding access to GLP-1 therapies while managing rising costs

Real-world research highlights patient persistence as a critical factor in achieving the long-term benefits of GLP-1 therapies

Polaris is awaiting an FDA decision for pegargiminase, an arginine degrading enzyme, for the treatment of malignant pleural mesothelioma (MPM) with non-epithelioid histology. The FDA granted the...

Learn with Biosimilar Basics. Part 1 starts with an overview of biosimilar products, sharing what biosimilar drugs are and the difference vs generic drugs.